|
Tuesday
|
Wednesday
|
Thursday
|
Friday
|
Saturday
|
|
THURSDAY, DECEMBER 7, 2017 |
|
|
|
|
|
7:00 am - 5:15 pm
|
Registration - Main Lobby |
|
| |
|
|
| 7:00 am - 9:00 am |
Spotlight on Novel Drugs/Predicting Response for HER2+ Breast Cancer - Stars at Night Ballroom 1&2 - 3rd Level |
|
| |
|
|
| 7:00 am - 9:00 am |
Spotlight on Signal Transduction and CDK4/6 Inhibitors - Stars at Night Ballroom 3&4 - 3rd Level |
|
| |
|
|
|
7:00 am - 9:00 am
|
POSTER SESSION 2 & continental breakfast
- Hall 1
|
|
|
|
|
|
|
|
Detection/Diagnosis
|
|
|
|
Circulating Tumor Cells
Circulating Markers
Diagnostic Pathology
|
P2-01
P2-02
P2-03
|
|
|
Tumor Cell and Molecular Biology
|
|
|
|
Epigenetics
Genomics
Tumor Heterogeneity/Molecular Subtypes
Molecular Profiles
Oncogenes/Tumor Suppressor Genes
|
P2-04
P2-05
P2-06
P2-07
P2-08
|
|
|
Prognostic and Predictive Factors |
|
|
|
Predictive Biomarkers for Targeted Therapies
Biomarkers for Chemotherapy
|
P2-09
P2-10
|
| |
Treatment |
|
| |
Radiotherapy
Breast Conservation
Neoadjuvant Endocrine Therapy
Toxicities - Management
Treatment - Other
|
P2-11
P2-12
P2-10
P2-11
P2-12 |
| |
|
|
| |
Rescheduled Abstracts |
P2-13 |
| |
|
|
|
9:00 am - 9:30 am
|
PLENARY LECTURE 2
– Hall 3 |
|
|
|
Advances in the Understanding of Mutational Signatures in Human Cells
Serena Nik-Zainal, MD, PhD
The Wellcome Trust Sanger Institute
Cambridge, UNITED KINGDOM
|
|
|
|
|
|
|
9:30 am - 11:30 am
|
GENERAL SESSION 3
– Hall 3
|
|
|
|
|
|
|
9:30 am
|
S3-01. A prospective randomized multi-center phase-III trial of additional 2 versus additional 5 years of Anastrozole after initial 5 years of adjuvant endocrine therapy - results from 3,484 postmenopausal women in the ABCSG-16 trial
|
|
|
|
Gnant M,Steger G, Greil R, Fitzal F, Mlineritsch B, Manfreda D, Tausch C, Balic M, Dubsky P, Moik M, Thaler J, Egle D, Bjelic-Radisic V, Selim U, Exner R, Singer C, Melbinger-Zeinitzer E, Haslbauer F, Stöger H, Helfgott R, Sevelda P, Trapl H, Wette V, Sölkner L, Jakesz R. Medical University of Vienna, Vienna, Austria; Paracelsus Medical University Salzburg , Salzburg, Austria; Doctor's Office Manfreda, Klagenfurt, Austria; Ordensklinkum Linz, Linz, Austria; Medical University Graz, Graz, Austria; Wels-Grieskirchen Medical Hospital, Wels, Austria; Medical University Innsbruck, Innsbruck, Austria; Medical University Graz, Graz, Austria; Hanusch Hospital, Vienna, Austria; Hospital Wolfsberg, Wolfsberg, Austria; Hospital Vöcklabruck, Vöcklabruck, Austria; Hospital Hietzing, Vienna, Austria; General Hospital Baden, Baden, Austria; Breast Center, Doctor´s Office Wette, St. Veit/Glan, Austria; ABCSG, Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria. |
|
|
9:45 am
|
S3-02. Plasma microRNA levels for predicting therapeutic response to neoadjuvant treatment in HER2-positive breast cancer: Results from Neo-ALTTO
|
|
|
|
Di Cosimo S, Appierto V, Tiberio P, Verderio P, Pizzamiglio S, Bottelli S, Iorio M, Baselga J, Piccart M, Huober J, Brase J, de la Pena L, Fumagalli D, de Azambuja E, de Braud F, Grazia Daidone M. Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy; Memorial Sloan Kettering Cancer Center, New York, NY; Université Libre de Bruxelles, Brussels, Belgium; Institut Jules Bordet, Brussels, Belgium; SOLTI breast cancer research group, Barcelona, Spain; Breast European Adjuvant Study Team, Brussels, Belgium; Universita¨ts-Frauenklinik, Ulm, Denmark; Novartis Pharmaceuticals, Basel, Switzerland.
|
|
|
10:00 am
|
S3-03. PAM50 intrinsic subtype as a predictor of pathological complete response following neoadjuvant dual HER2 blockade without chemotherapy in HER2-positive breast cancer: First results of the PAMELA clinical trial
|
|
|
|
Prat Aparicio A, Cortes Castan J, Pare L, Galvan P, Bermejo B, Martínez N, Vidal M, Pernas S, López R, Muñoz M, Nuciforo P, Fasani R, Morales S, Oliveira M, de La Peña L, Peláez A, Llombart A. Hospital Clinic de Barcelona, Barcelona, Spain; Hospital Ramón y Cajal, Madrid, Spain; Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Vall d'Hebron Instituto de Oncología (VHIO), Barcelona, Spain; Hospital Clínico de Valencia, Valencia, Spain; Instituto Catalán de Oncología, Hospitalet, Barcelona, Spain; Complejo Universitario de Santiago de Compostela (CHUS), Santiago de Compostela, Galicia, Spain; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitari Vall d' Hebron, Barcelona, Spain; SOLTI, Breast Cancer Research Group, Barcelona, Spain; Hospital Arnau de Vilanova de Valencia, Valencia, Spain.
|
|
|
10:15 am
|
S3-04. Primary analysis of PERTAIN: A randomized, two-arm, open-label, multicenter phase II trial assessing the efficacy and safety of pertuzumab given in combination with trastuzumab plus an aromatase inhibitor in first-line patients with HER2-positive and hormone receptor-positive metastatic or locally advanced breast cancer
|
|
|
|
Arpino G, Ferrero J-M, de la Haba-Rodriguez J, Easton V, Schuhmacher C, Restuccia E, Rimawi M. Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX; Département d'Oncologie Médicale, Centre Antoine Lacassagne, Nice, France; Oncology Department, Maimonides Institute of Biomedical Research, Reina Sofía Hospital, University of Córdoba, Córdoba, Spain; F. Hoffmann-La Roche Ltd, Basel, Switzerland; Department of Clinical Medicine and Surgery, Università degli Studi di Napoli Federico II, Naples, Italy.
|
|
|
10:30 am
|
S3-05. Integrated analysis of multidimensional genomic data on CALGB 40601 (Alliance), a randomized neoadjuvant phase III trial of weekly paclitaxel (T) and trastuzumab (H) with or without lapatinib (L) for HER2-positive breast cancer
|
|
|
|
Tanioka M, Fan C, Carey LA, Hyslop T, Pitcher BN, Parker JA, Hoadley KA, Henry NL, Tolaney S, Dang C, Krop IE, Harris L, Berry DA, Mardis E, Perou CM, Winer EP, Hudis CA. University of North Carolina, Chapel Hill, NC; Alliance Statistics and Data Center, Duke University, Durham, NC; University of Michigan, Ann Arbor, MI; Dana Farber Cancer Institute, Boston, MA; Memorial Sloan Kettering Cancer Center, New York, NY; National Cancer Institute, Bethesda, MD; Alliance Statistics and Data Center, MD Anderson, Houston, TX; Washington University, St. Louis, MO.
Maki Tanioka, MD, PhD is a recipient of an AACR Scholar-in-Training Award. |
|
|
10:45 am
|
S3-06. A phase III trial evaluating pCR in patients with HR+, HER2-positive breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP) +/- estrogen deprivation: NRG oncology/NSABP B-52
|
|
|
|
Rimawi MF, Cecchini RS, Rastogi P, Geyer CE, Fehrenbacher L, Stella PJ, Dayao Z, Rabinovitch R, Dyar SH, Flynn PJ, Baez-Diaz L, Paik S, Swain SM, Mamounas EP, Osborne CK, Wolmark N. NRG Oncology/NSABP (NSABP Legacy trials are now part of the NRG Oncology portfolio); Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston; University of Pittsburgh; The University of Pittsburgh Cancer Institute; Massey Cancer Center, Virginia Commonwealth University; Kaiser Permanente Oncology Clinical Trials Northern California, Vallejo; Michigan Cancer Research Consortium NCORP; New Mexico Minority Underserved NCORP/ University of New Mexico Cancer Center; University of Colorado Cancer Center LAPS; Southeast Clinical Oncology Research (SCOR) Cancer Control Consortium NCORP; Metro Minnesota Community Oncology Research Consortium; Puerto Rico Minority Underserved NCORP, San Juan; Severance Biomedical Science Institute and Department of Medical Oncology, Yonsei University College of Medicine; Washington Cancer Institute, Medstar Washington Hospital Center; UF Cancer Center at Orlando Health; Baylor College of Medicine/UT Health Science Center, San Antonio; Allegheny Health Network Cancer Institute.
|
|
|
11:00 am
|
S3-07. Impact of radiotherapy on complications and patient-reported satisfaction with breast reconstruction: Findings from the prospective multicenter MROC study
|
|
|
|
Jagsi R, Momoh AO, Qi J, Hamill JB, Billig J, Kim HM, Pusic AL, Wilkins EG. University of Michigan, Ann Arbor, MI; Memorial Sloan Kettering Cancer Center, New York, NY.
|
|
|
11:15 am
|
S3-08. Radioactive seed localization versus wire guided localization of nonpalpable invasive and in situ breast cancer: A Danish multicenter randomized controlled trial
|
|
| |
Langhans L, Tvedskov TF, Klausen TL, Jensen M-B, Talman M-L, Vejborg I, Benian C, Rosilind A, Hermansen J, Oturai PS, Bentzon N, Kroman N. Rigshospitalet, University of Copenhagen, Copenhagen, Denmark; Danish Breast Cancer Cooperative Group, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark; Herlev Hospital, University of Copenhagen, Denmark, Herlev, Denmark; Herlev Hospital, University of Copenhagen, Herlev, Denmark
Linnea Langhans, MD is a recipient of an SABCS Clinical Scholars Award.
|
|
| |
|
|
| 11:00 am - 5:00 pm |
EXHIBITS - Hall 2 |
|
| |
|
|
|
11:30 am - 12:00 pm |
AACR Distinguished Lectureship in Breast Cancer Research - Hall 3
|
|
| |
|
|
|
12:00 pm - 1:00 pm |
BREAK |
|
|
|
|
|
|
1:00 pm - 2:00 pm
|
CASE DISCUSSION 1 – Stars at Night Ballroom 1&2 - 3rd Level
|
|
|
|
Moderator: Mothaffar Rimawi, MD
Baylor College of Medicine
Houston, TX
Panelists:
TBD
|
|
| |
|
|
|
1:00 pm - 2:00 pm
|
BASIC SCIENCE FORUM 2 - Stars at Night Ballroom 3&4 - 3rd Level |
|
|
|
Mechanisms of Early Dissemination and Metastasis
Moderator: TBD
Ocogenic and microenvironmental signals driving early dissemination, dormancy and metastasis
Julio A. Aguirre-Ghiso, PhD
Mount Sinai School of Medicine
New York, NY
The perivascular niche protects dormant disseminated tumor cells from therapy
Cyrus M. Ghajar, PhD
Fred Hutchinson Cancer Research Center
Seattle, WA
|
|
| |
|
|
|
2:15 pm - 3:15 pm
|
MINI-SYMPOSIUM 1 - Hall 3 |
|
|
|
Molecular Subtypes and Clinical Ramifications of TNBC
Moderator: Tiffany A. Traina, MD
Memorial Sloan Kettering Cancer Center
New York, NY
Gene expression and clinical implications. Approach to target discovery
Samuel Aparicio, PhD
The University of British Columbia
Vancouver, CANADA
New clinical approaches for TNBC
Melinda Telli, MD
Stanford University School of Medicine
Stanford, CA
|
|
|
|
|
|
|
3:15 pm - 5:00 pm
|
GENERAL SESSION 4
– Hall 3
Moderator:
Sarat Chandarlapaty, MD, PhD
Memorial Sloan Kettering Cancer Center
New York, NY
|
|
|
|
|
|
|
3:15 pm
|
S4-01. A novel BRD4 inhibitor enhances endocrine therapy efficacy and circumvents endocrine-resistance in estrogen receptor-positive breast cancer models
|
|
|
|
De Angelis C, Nardone A, Letizia Cataldo M, Fu X, Trivedi M, Yi S, Breckenridge D, Chamnsess GC, Vitorino P, Osborne CK, Schiff R. Lester & Sue Smith Breast Center, Baylor College of Medicine, Houston, TX; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX; Department of Medicine, Baylor College of Medicine, Houston, TX; Department of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, Houston, TX; Gilead Science, Foster City, CA.
|
|
| 3:30 pm
|
S4-02. The Y537S ESR1 mutation is a dominant driver of distant ER-positive breast cancer metastasis
|
|
|
|
Fuqua, SAW, Gu G, Rechoum Y, Gelsomino L, Dustin DJ, Corona-Rodriguez A, Beyer AR, Pejerrey SM, Gao M, Tsimelzon A, Tian L, Zhang X, Nagi C, Ando' S. Baylor College of Medicine, Houston, TX; University of Calabria, Cosenza, Calabria, Italy; MD Anderson Cancer Center, Houston, TX.
|
|
| 3:45 pm
|
S4-03. Targeted and selective degradation of estrogen receptor (ER) alpha by PROTACs
|
|
|
|
Flanagan JJ, Rossi AK, Andreoli M, Willard RR, Gordon D, Harling J, Churcher I, Smith I, Zinn N, Bantscheff M, Crews CM, Crew A, Coleman KG, Winkler JD, Qian Y. Arvinas LLC, New Haven, CT; GSK Medicines Research Centre, Stevenage, United Kingdom; Yale University, New Haven, CT.
|
|
|
4:00 pm
|
S4-04. Tumor microenvironment of metastasis (TMEM) score is associated with early distant recurrence in hormone receptor (HR) positive, HER2-negative early stage breast cancer (ESBC)
|
|
|
|
Sparano JA, Gray R, Oktay MH, Entenberg D, Rohan T, Xue X, Donovan M, Peterson M, Shuber A, Hamilton D, D'Alfonso T, Goldstein LJ, Gerlter F, Davidson N, Condeelis J, Jones J. Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY; ECOG-ACRIN Research Group, Boston, MA; Albert Einstein College of Medicine, Bronx, NY; Mt. Sinai School of Medicine, New York, NY; MetaStat, Inc, Boston, MA; Weill Cornell Medical College, New York, NY; Fox Chase Cancer Center, Philadelphia, PA; Massachusetts Institute of Technology, Boston, MA; University of Pittsburgh Cancer Institute, Pittsburgh, PA.
|
|
|
4:15 pm
|
S4-05. Expression of the DEK oncogene promotes M2 polarization and iron recycling in tumor associated macrophages
|
|
| |
Privette Vinnedge LM, Pease NA, Cheek J. Cincinnati Children's Hospital Medical Center, Cincinnati, OH. |
|
| 4:30 pm |
S4-06. P2-10-03 Moved from Poster Session 2
Biological effects of abemaciclib in a phase2 neoadjuvant study for postmenopausal patients with hormone receptor positive, HER2 negative breast cancer
|
|
| |
Hurvitz S, Martin M, Fernández Abad M, Chan D, Rostorfer R, Petru E, Barriga S, Costigan TM, Caldwell CW, Nguyen T, Press M, Slamon D. University of California, Los Angeles, CA; Hospital General Universitario Gregorio Marañón, Madrid, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Cancer Care Associates, Redondo Beach, CA; UF Health Cancer Center at Orlando Health, Orlando, FL; Medical University Graz, Graz, Steiermark, Austria; Eli Lilly and Company, Madrid, Spain; Eli Lilly and Company, Indianapolis, IN; University of Southern California, Los Angeles, CA. |
|
| |
|
|
| 4:45 pm |
S4-07. P4-22-01 Moved from Poster session 4
BELLE-3: A Phase III study of buparlisib + fulvestrant in postmenopausal women with HR+, HER2-, aromatase inhibitor-treated, locally advanced or metastatic breast cancer, who progressed on or after mTOR inhibitor-based treatment |
|
| |
Di Leo A, Keun SL, Ciruelos E, Lønning P, Janni W, O'Regan R, Mouret Reynier M-A, Kalev D, Egle D, Csoszi T, Bordonaro R, Decker T, Tjan-Heijnen VC, Blau S, Schirone A, Weber D, El-Hashimy M, Goteti S, Germa C, Bachelot T. Ospedale Misericordia e Dolce, Prato, Italy; National Cancer Center, Gyeonggi-do, Republic of Korea; Hospital Universitario 12 de Octubre, Madrid, Spain; Haukeland University Hospital, Bergen, Norway; Universitätsklinikum Ulm, Ulm, Germany; University of Wisconsin, Madison, WI; Centre Jean Perrin, Clermont-Ferrand, France; Medical University of Varna, Varna, Bulgaria; Univ Frauenklinik Innsbruck, Innsbruck, Austria; JNSZ Megyei Hetényi Géza Kórház-Rendelőintézet, Szolnok, Hungary; ARNAS Garibaldi, Catania, Italy; Onkonet - Onkologie Ravensburg, Ravensburg, Germany; Maastricht University Medical Center, Maastricht, Netherlands; Rainier Hematology-Oncology/Northwest Medical Specialities, LLC, Tacoma, WA; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, Italy; Novartis Pharma AG, Basel, Switzerland; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Centre Léon Bérard, Lyon, France. |
|
| |
|
|
|
5:00 pm - 7:00 pm
|
Spotlight on Endocrine Therapy – Stars at Night Ballroom 1&2 - 3rd Level
|
|
| |
|
|
| 5:00 pm - 7:00 pm |
Spotlight on Immuno Oncology - Stars at Night Ballroom 3&4 - 3rd Level |
|
| |
|
|
|
5:00 pm - 7:00 pm
|
POSTER SESSION 3 & reception – Hall 1 |
|
|
|
|
|
|
Detection/Diagnosis
Axillary Staging and Sentinel Nodes
Biopsy Techniques
|
P3-01
P3-02
|
|
|
|
|
|
|
Tumor Cell and Molecular Biology
Genetics - Germline Changes
Genetics - Somatic Changes
Immunology and Preclinical Immunotherapy
New Drugs and Mechanisms
Novel/Emerging Therapeutic Targets
|
P3-03
P3-04
P3-05
P3-06
P3-07
|
|
|
|
|
|
|
Prognostic and Predictive Factors
Prognostic Factors - Clinical Testing and Validation
|
P3-08
|
|
|
|
|
| |
Epidemiology, Risk and Prevention
Risk Factors and Modeling
Other |
P3-09
P3-10 |
|
|
Treatment
Advanced Endocrine Therapy
Adjuvant Endocrine Therapy
Neoadjuvant Endocrine Therapy
Toxicities-Management
Other
TIssue and Data Banks
Clinical Trial Design and Management
|
P3-11
P3-12
P3-13
P3-14
P3-15
P3-16
P3-17
|
|
|
|
|
Ongoing Clinical Trials 2
Ongoing Trials - Surgery
Ongoing Trials - Conservation Surgery
Ongoing Trials - Radiotherapy
Ongoing Trials - Photodynamic Therapy
Chemotherapy
Metastases
New Agents and Strategies
|
OT2-01
OT2-02
OT2-03
OT2-04
OT2-05
OT2-06
OT2-07
|
| |
|
|
| 7:30 pm |
OPEN SATELLITE EVENT
TBD
|
|
|